Web Date: August 28, 2017
Gilead to acquire Kite Pharma for $11.9 billion
In a bid to diversify its portfolio and boost growth, Gilead Sciences has agreed to acquire Kite Pharma, a Santa Monica, Calif.-based immunotherapy specialist focused on cancer, for $11.9 billion. Gilead, which focuses on treatments for infectious disease, is following up its $11 billion acquisition of Pharmasset in 2011, a deal that landed the Foster City, Calif.-based firm the hepatitis C drugs Sovaldi and Harvoni.
Kite is a leader in the emerging field of cell . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society